企业QQ
官方微信
Antibody Phage Display (scFv)NeoClone is a world-class custom antibody development company, having discovered hundreds of antibodies for our clients. But there are very difficult targets out there that hybridoma technology alone can’t solve. So we added antibody phage display capabilities to help us develop the diverse and specific antibody repertoire to difficult targets that you need. Our team now has over 15 years of scFv phage antibody and recombinant antibody experience. Greater Diversity, Faster AnswersOne of the advantages of phage display is the enormous diversity of variant antibody genes that can be represented in a phage library, even to relatively non-immunogenic targets. NeoClone’s antibody phage display service provides a means of rapidly screening large numbers of scFv in our antibody gene libraries against potential binding partners in only 2 weeks. Once promising clones are identified, we can clone, express and sequence the scFv antibodies for your further evaluation. Based on your needs, we can engineer the antibody further for expression in mammalian cells, affinity maturation or other optimization steps. NeoClone can also construct new scFv phage libraries from immunized or naïve donors from several species. Antibody Phage Display ScreeningNeoClone's proprietary antibody phage display screening method allows for efficient, high throughput identification of rare binders with distinctive characteristics required for a specific application. NeoClone is able to generate scFv antibodies that target antigens that have traditionally been difficult to attain, including Post-Translationally Modified peptides (PTMs) such as acetylated or phosphorylated antigens. In addition, NeoClone can express the specific phage as scFv-Fc in mammalian cell culture or by periplasmic expression in bacteria. The image below shows the results of screening for a phospho-peptide specific scFv in one of our antibody phage display libraries. Four individual clones recognized the phospho-peptide (P-Myb) but not the un-phosphorylated peptide (Myb).
Antibody Phage Display Library ConstructionHow does that work? Click on the image below for an overview. 
C. M. Hammers & J. R. Stanley, Journal of Investigative Dermatology (2013) 134, e17. doi:10.1038/jid.2013.521
If you are interested in starting an antibody project with NeoClone, please contact us. |
蚂蚁淘生物是一家专门从事抗体,蛋白,细胞等试剂产品研发与销售的公司.蚂蚁淘生物专业代理NeoCloneX 品牌试剂,大量现货,保证正品,价格优惠.欢迎来询
苏州蚂蚁淘生物科技有限公司成立于2009年，是一家专业提供实验室整体采购方案的专业公司，为广大采购和实验室解决了大量问题，几年来已经成为几乎所有合作伙伴最优秀的合作伙伴，我们一直秉承信誉第一的原则，坚持不卖假货，哪怕利润损失也要为客户提供最好的产品。我们已经和国外500多个品牌建立了贸易往来，并在国际上享有相当知名度，现已经成为国外近100个品牌中国指定代理，并成为其中国最优秀的代理商。我们部分客户1：经销商代表---国药化试，飞世尔，SIGMA，等1000家左右的经销商2：学校代表---北京大学，清华大学，上海交通大学，复旦大学，浙江大学，武汉大学，厦门大学.....等200所左右大学及100多家附属医院3：制药公司代表：罗氏，阿斯利康，诺和诺德，和记黄埔，东阳光科......4：CRO公司代表：睿智化学，药明康德，桑迪亚，美迪西......我们现有代理品牌如下，还在不断增加中
NeoClone's Management Team Deven McGlenn - Chief Executive Officer Deven McGlenn is CEO of NeoClone and has been involved with the company since inception in 1999 and full-time since April 2002. During his tenure he has grown the business to $7M+ in revenues, 15+ FTEs and raised over $2.5M in equity. Prior to NeoClone, he was a management consultant for Arthur Andersen where he helped Fortune 500 companies develop a strategic view of their risk profiles. Before Andersen, he was the founder and CEO of an environmental remediation firm headquartered in the Midwest. Deven has a BS in Political Science with a minor in Business Administration from Marquette University. Contact Deven directly. Mark Sullivan, PhD - Director of Phage Technologies Dr. Sullivan is the Director of Phage Technologies at NeoClone. He has years of experience manipulating immunoglobulin molecules to develop novel reagents using phage antibody technology. Dr. Sullivan is an expert in the creation of scFv libraries using novel strategies that eliminate common problems associated with production and use of complex Ab libraries. Mark has worked at the University of Rochester, Johnson & Johnson and Eastman Kodak. He received his PhD from the University of Wisconsin-Madison and his BS from Purdue University. For questions relating to antibody phage display, please contact Mark.
